We agree with Pereira et al,26 who proposed that plasma GFAP “should be incorporated in models of Alzheimer’s disease pathogenesis,” in that it may detect early astrocytosis secondary to amyloid-β pathology, but we would add consideration of elevated plasma P-tau181 and other biomarkers. This evidence concerns the gene GFAP and Alzheimer disease.